Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
Gilead has conducted an analysis of genetic information currently available for the Omicron variant and found no additional prevalent mutations
A forum for researchers, students and applicants in the field of cyclodextrin technology
Gilead has conducted an analysis of genetic information currently available for the Omicron variant and found no additional prevalent mutations
Angiotensin‐converting enzyme 2 (ACE2) has been identified as the main receptors for SARS‐CoV and SARS‐CoV‐2. Soluble ACE2 (sACE2) can bind
Researchers led by Professor Peter Horby at the University of Oxford, in England say they have the first evidence that
Vaccines against COVID-19 will hopefully give broad parts of the human population a safe level of immunity and are considered
The government of the U.K. is granting the country’s equivalent to an emergency use authorization to remdesivir, the antiviral drug
According to Hindustan Times, Bangladesh’s Beximco Pharmaceuticals Ltd. has become the world’s first company to start selling the generic version
Coronavirus is a family of viruses that cause respiratory infections.The new coronavirus agent was discovered on 12/31/19 after cases registered
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand
Japan approved the Gilead Sciences antiviral drug remdesivir Thursday for treatment of severe COVID-19 patients, under an exceptional approval pathway
UC Berkeley, Excivion and Cyclolab announce a supplemental grant awarded to UC Berkeley by the National Institutes of Health to evaluate a wide